Abstracts tagged "prevention"

Abstract Number: 1274 • ACR Convergence 2022
Improving Pneumococcal Vaccination Rates Among Immunosuppressed Adults in an Academic Rheumatology Clinic Utilizing a Nurse Driven Protocol
Elena Joerns¹, Nagendra Pokala², Dan Wang³, Joan Reisch³, Reuben Arasaratnam³, Bonnie Bermas¹ and Puneet Bajaj³, ¹UT Southwestern, Dallas, TX, ²University of Texas Southwestern Medical Center, Dallas, TX, ³UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Rheumatology patients are at risk for severe pneumococcal infections due to their underlying disease and immunosuppressive therapy. Current Advisory Committee on Immunization Practices guidelines…
Abstract Number: 0549 • ACR Convergence 2022
Efficacy and Safety of the SARS-CoV-2 Vaccine in Patients with Rheumatoid Arthritis
Esther Vicente-Rabaneda¹, María Torres², Miren Uriarte³, Patricia Quiroga-Colina³, Ainhoa Gutiérrez⁴, Ana Triguero⁵, Francisco Gutiérrez³, Noelia García³, Ana Romero-Robles³, Laura Cardeñoso⁴ and Santos Castañeda¹, ¹Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ²Medical student, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁴Division of Microbiology, Hospital Universitario de La Princesa, Madrid, Spain, ⁵Hospital Universitario La Princesa, Madrid, Spain
Background/Purpose: To describe the efficacy and safety of the SARS-CoV-2 vaccine in a series of patients with rheumatoid arthritis (RA).Methods: Retrospective observational study of RA…
Abstract Number: 1275 • ACR Convergence 2022
Pneumococcal Vaccination Compliance Rate Among Lupus and Rheumatoid Arthritis Patients in Rheumatology Fellow’s Cllinic
Sana Kang¹, George Gennaoui² and J. Patricia Dhar³, ¹Ascension St John Hospital, Chesterfield, MO, ²Ascension St. John Hospital, St. Clair Shores, MI, ³Ascension St. John Hospital and Wayne State University School of Medicine, Bloomfield Hills, MI
Background/Purpose: The US Center for Disease Control and Prevention recommends that adults ages 19 years and older, with immunocompromising conditions should receive a dose of…
Abstract Number: 0616 • ACR Convergence 2022
Serum Proteomic Networks Associate with Pre-clinical Rheumatoid Arthritis Autoantibodies and Longitudinal Outcomes
Liam O'Neil¹, XIAOBO MENG¹, Caitin McFadyen¹, Marvin Fritzler² and Hani El-Gabalawy¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of Calgary, Calgary, AB, Canada
Background/Purpose: The detection of anti-citrullinated protein antibodies (ACPA) is associated with increased risk for development of future Rheumatoid Arthritis (RA). The biological events that underpin…
Abstract Number: 1323 • ACR Convergence 2022
Secondary Prevention of Vertebral Fractures Sustained Efficacy over Time
JOSE ELOY OLLER RODRIGUEZ¹, Elena Grau García², Samuel Leal Rodriguez³, Laura Mas Sanchez², Pablo Francisco Muñoz Martínez⁴, Carmen Riesco Bárcena⁵, Anderson Huaylla Quispe⁶, Cristobal Pavez Perales², Francisco Miguel Ortiz Sanjuan⁷, José Ivorra Cortés², Inés Cánovas Olmos², Luis González Puig⁸, Isabel Martínez-Cordellat², Carmen Nájera Herranz⁷, Rosa Negueroles Albuixech², Elvira Vicens Bernabeu⁷, Alba Torrat Novés⁵, Daniel Ramos Castro² and José andrés Román ivorra³, ¹Hospital Universitario de La Fe, València, Spain, ²Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Spain, ³Hospital Universitari i Politécnic La Fe, València, Spain, ⁴Hospital Universitario y Politécnico La Fe, València, Spain, ⁵Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, ⁶Medicina, València, Spain, ⁷Hospital Universitario de La Fe, València, ⁸Rheumatology Department. Hospital Universitario y Politécnico La Fe, Torrente, Valencia, Spain
Background/Purpose: Vertebral fractures entail a notorious social and health problem, and their presence is the greatest risk factor for the appearance of a new vertebral…
Abstract Number: 0703 • ACR Convergence 2022
Vaccination Against SARS-CoV2 in Patients with Systemic Autoimmune Diseases: A Safety Report from EULAR COVAX Registry
Jose A Gomez-Puerta¹, Ana Lúcia Martins Fernandes², Juan Camilo Sarmiento-Monroy¹, Saskia Lawson-Tovey³, Kimme Hyrich⁴, Laure Gossec⁵, Loreto Carmona⁶, Anja Strangfeld⁷, Elsa Mateus⁸, Ana Maria Rodrigues⁹, Eric Hachulla¹⁰, Marta Mosca¹¹, Patrick Durez¹², Bernd Raffeiner¹³, Nicolas Roux¹⁴, Viellard Eric¹⁵, Olivier Brocq¹⁶, Julija Zepa¹⁷, Eva Strakova¹⁸, Inita Bulina¹⁹, Vanda Mlynarikova²⁰, Emoke Šteňová²¹, Martin Soubrier²², Xavier Mariette²³ and Pedro Machado²⁴, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Centro Hospitalar Universitário do Algarve, Faro, Portugal, ³Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, the University of Manchester, Manchester, UK AND National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴The University of Manchester, Manchester, United Kingdom, ⁵Sorbonne Université, Paris, France, ⁶Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁷Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁸EULAR, Lisboa, Portugal, ⁹Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal, ¹⁰University of Lille, LILLE, France, ¹¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹²Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ¹³Department of Rheumatology, Central Hospital of Bolzano, Bolzano, Italy, ¹⁴Service de Rhumatologie, Hôpital Robert Schuman, Metz, France, ¹⁵Private practice, St. Malo, France, ¹⁶Rheumatology- CH Princesse Grace, Monaco, Monaco, ¹⁷Riga Stradins University, Latvia, Pauls Stradins Clinical University Hospital, Centre of Rheumatology, Riga, Latvia, Riga, Latvia, ¹⁸Department of Internal Medicine, Faculty Hospital Prešov, Presov, Slovakia, ¹⁹Pauls Stradins Clinical University Hospital, Riga, Riga, Latvia, ²⁰National Institute of Rheumatic Diseases, Piešťany, Slovakia, ²¹University Hospital, Bratislava, Slovakia, ²²Gabriel-Montpied Hospital, Clermont-Ferrand, France, ²³Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ²⁴University College London, London, United Kingdom
Background/Purpose: Some concerns have been raised with the use of vaccines against SARS-CoV-2 in patients with Systemic Autoimmune Diseases (SAD) including the risk of serious…
Abstract Number: 1391 • ACR Convergence 2022
Inadequate Cardiovascular Disease Risk Screening and Preventative Treatment in Patients with Rheumatoid Arthritis
Tooba Munawar¹, Farzam Khokhar² and Andras Perl³, ¹SUNY Upstate Medical Unviersity, Jamesville, NY, ²SUNY Upstate Medical University, Syracuse, NY, ³SUNY, Syracuse, NY
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease. Patients with RA are at risk of accelerated cardiovascular disease (CVD). The purpose of this study…
Abstract Number: 0720 • ACR Convergence 2022
Risk-Benefit Assessment of Primary Prophylaxis for Pneumocystis Pneumonia in Patents with Rheumatic Diseases Exposed to Rituximab: A Multicenter Cohort Study
Jun Won Park¹, Jeffrey Curtis², Min Jung Kim³, You-Jung Ha⁴, Yun Jong Lee⁴ and Eun Bong Lee¹, ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, Republic of Korea, ⁴Seoul National University Bundang Hospital, Seongnam, Republic of Korea
Background/Purpose: Although previous studies suggested that primary prophylaxis for pneumocystis pneumonia (PJP) during rituximab treatment could be beneficial, it is uncertain whether this strategy should…
Abstract Number: 1596 • ACR Convergence 2022
The Role of Coronary Calcium Screening in Patients with Lupus Who Appear to Be at Low Cardiovascular Risk
Sarah Stoots¹, Joshua Baker¹ and Joan Von Feldt², ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Wilmington, DE
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) are at elevated cardiovascular risk. However, common risk calculators such as the atherosclerotic cardiovascular disease (ASCVD) risk estimator…
Abstract Number: 0727 • ACR Convergence 2022
Primary Prevention of Fractures in Osteoporotic Patients in a Southern California Academic Health System
Eugene Looi¹, Gergana Mishkova¹ and Christina Downey², ¹Loma Linda University, Loma Linda, CA, ²Loma Linda University Medical Center, Redlands, CA
Background/Purpose: Osteoporosis (OSP) is common, carries high morbidity, significant cost and remains underrecognized and undertreated by health care providers (1). At a university-based academic health…
Abstract Number: 1603 • ACR Convergence 2022
Intervention with Methotrexate in Arthralgia at Risk for Rheumatoid Arthritis to Reduce the Development of Persistent Arthritis and Its Disease Burden (TREAT EARLIER): A Double-blind, Randomized, Placebo-controlled Trial
Doortje Krijbolder¹, Marloes Verstappen¹, Bastiaan van Dijk², Yousra Dakkak¹, Aleid Boer¹, Yune-Jung Park¹, Marianne E. de Witt-Luth³, Karen Visser⁴, Marc Kok⁵, Esmeralda T.H. Molenaar⁶, Pascal de Jong⁷, Stephan Böhringer⁸, Tom Huizinga¹, CF Allaart¹, Ellis Niemantsverdriet⁹ and Annette van der Helm-van Mil¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre (LUMC), Leiden, Netherlands, ³Reinier de Graaf Ziekenhuis, Delft, Netherlands, ⁴Haga Ziekenhuis, Amsterdam, Netherlands, ⁵Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam, Netherlands, ⁶Groene Hart Ziekenhuis, Gouda, Netherlands, ⁷ErasmusMC, Hendrik Ido Ambacht, Netherlands, ⁸Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Leiden, Netherlands, ⁹LUMC, Leiden, Netherlands, ¹⁰Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is the most common autoimmune disease and requires long term treatment to suppress inflammation. Currently, treatment is started when arthritis is…
Abstract Number: 0781 • ACR Convergence 2022
Rituximab Treated Patients with Hypogammaglobulinemia Are Less Likely to Seroconvert Following SARS-CoV-2 Vaccine Supplemental Dose
Daniel Magliulo¹, Vasileios Kyttaris¹ and Emily Rose², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, West Roxbury, MA
Background/Purpose: Rituximab (RTX) is a very effective treatment for autoimmune rheumatic diseases (AIRD). However, treatment increases risk of infections and impairs responses to vaccines. Prior…
Abstract Number: 1604 • ACR Convergence 2022
Hydroxychloroquine Does Not Prevent the Future Development of Rheumatoid Arthritis in a Population with Baseline High Levels of Antibodies to Citrullinated Protein Antigens and Absence of Inflammatory Arthritis: Interim Analysis of the StopRA Trial
Kevin D Deane¹, Christopher Striebich², Marie Feser³, Kristen Demoruelle³, LauraKay Moss⁴, Elizabeth Bemis³, Ashley Frazer-Abel⁴, Chelsie Fleischer⁴, Jeffrey Sparks⁵, Elizabeth Solow⁶, Judith James⁷, Joel Guthridge⁷, John Davis⁸, Jonathan Graf⁹, Jonathan Kay¹⁰, Maria Danila¹¹, S. Louis Bridges, Jr.¹², Lindsy Forbess¹³, James O'Dell¹⁴, Maureen McMahon¹⁵, Jennifer Grossman¹⁵, Diane Horowitz¹⁶, Athan Tiliakos¹⁷, Elena Schiopu¹⁸, David Fox¹⁹, Jeffrey Carlin²⁰, Cristina Arriens⁷, Vivian Bykerk¹², Reem Jan²¹, Mathilde Pioro²², M. Elaine Husni²³, Ana Fernandez-Pokorny²⁴, Sarah Walker²⁵, Susan Booher²⁶, Melissa Greenleaf²⁷, Margie Byron²⁵, Lynette Keyes-Elstein²⁵, Ellen Goldmuntz²⁸ and V. Michael Holers²⁹, ¹University of Colorado Denver Anschutz Medical Campus, Denver, CO, ²University of Colorado, Aurora, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴University of Colorado Denver, Denver, CO, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶UT Southwestern Medical Center, Dallas, TX, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Mayo Clinic, Rochester, MN, ⁹Ucsf, San Francisco, CA, ¹⁰Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, ¹¹University of Alabama at Birmingham, Birmingham, AL, ¹²Hospital for Special Surgery, New York, NY, ¹³Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁴University of Nebraska Medical Center, Omaha, NE, ¹⁵University of California Los Angeles, Los Angeles, CA, ¹⁶Northwell Health, Jericho, NY, ¹⁷Emory University, Roswell, GA, ¹⁸Michigan Medicine, Ann Arbor, MI, ¹⁹University of Michigan, Ann Arbor, MI, ²⁰Virginia Mason Medical Center, Seattle, WA, ²¹University of Chicago, Chicago, IL, ²²University of Washington, Seattle, WA, ²³Cleveland Clinic, Cleveland, OH, ²⁴Essentia Health, Duluth, MN, ²⁵Rho, Chapel Hill, NC, ²⁶NIH NIAID, Bethesda, MD, ²⁷NIH, Rock Hill, SC, ²⁸NIAID/ NIH, Washington, DC, ²⁹University of Colorado, Denver, CO
Background/Purpose: The Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (StopRA) (ClinicalTrials.gov NCT02603146) is a randomized, double-masked, placebo-controlled, multi-center (20 sites) clinical trial evaluating…
Abstract Number: 0800 • ACR Convergence 2022
Antibody Response to Shingrix Vaccination in Patients with Rheumatoid Arthritis, Seronegative Spondyloarthropathy and Systemic Lupus Erythematosus on Immunosuppressive Medications
Alina Kifayat¹, amy Wasserman², Kirk Sperber¹, Deana Nes³, Paul Arnaboldi⁴ and Julia Ash⁵, ¹New York Medical College at Westchester Medical Center, Valhalla, NY, ²New York Medical College at Westchester Medical Center, Armonk, NY, ³Bergen Medical Associates, Ridgewood, NJ, ⁴New York Medical College, Valhalla, NY, ⁵New York Medical College at Westchester Medical Center, Dobbs Ferry, NY
Background/Purpose: In patients with rheumatic diseases herpes zoster (HZ) has been identified as one of the most common infections associated with immunosuppression. Shingrix is a…
Abstract Number: 1612 • ACR Convergence 2022
Prediction of Psoriatic Arthritis Tool (PRESTO): Development and Performance of a New Scoring System for Psoriatic Arthritis Risk
Lihi Eder¹, Ker-Ai Lee², Vinod Chandran³, Jessica Widdifield⁴, Aaron Drucker⁴, Christopher Ritchlin⁵, Cheryl F Rosen⁴, Richard Cook² and Dafna Gladman⁶, ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁶Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: A simple, scalable tool that identifies psoriasis patients at high risk for developing PsA could improve early detection and facilitate early intervention. Our overall…

« Previous Page
1
…
5
6
7
8
9
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].